Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

9.24
-0.0200-0.22%
Volume:22.98K
Turnover:212.73K
Market Cap:466.75M
PE:-2.69
High:9.37
Open:9.23
Low:9.23
Close:9.26
52wk High:13.48
52wk Low:5.04
Shares:50.51M
Float Shares:41.42M
Volume Ratio:1.05
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4333
EPS(LYR):-4.5871
ROE:-62.49%
ROA:-17.88%
PB:2.18
PE(LYR):-2.01

Loading ...

Leerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
2 hours ago

CEO Curran Simpson Reports Disposal of Regenxbio Inc. Common Shares

Reuters
·
Sep 13

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Sep 08

BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii

Reuters
·
Sep 05

REGENXBIO Inc. Announces Positive 12-Month Pivotal Data for RGX-121 in Hunter Syndrome Treatment Trial

Reuters
·
Sep 05

Regenxbio Inc - Primary Endpoint of Csf Hs D2s6 Reduction Met

THOMSON REUTERS
·
Sep 05

Regenxbio Inc - Rgx-121 Improves Outcomes for Mps Ii Patients

THOMSON REUTERS
·
Sep 05

Regenxbio Inc - FDA Decision on Rgx-121 Expected by February 8, 2026

THOMSON REUTERS
·
Sep 05

REGENXBIO Inc. to Participate in Wells Fargo Healthcare Conference in Boston

Reuters
·
Aug 28

REGENXBIO Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 19

BRIEF-Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II

Reuters
·
Aug 19

BUZZ-Regenxbio falls after FDA extends review of genetic disorder therapy

Reuters
·
Aug 19

REGENXBIO Inc. Announces FDA Extension of Review Timeline for RGX-121 BLA to February 2026 for Hunter Syndrome Therapy

Reuters
·
Aug 19

Regenxbio Inc - Pdufa Date Extended to February 8, 2026

THOMSON REUTERS
·
Aug 19

Regenxbio Announces FDA Review Extension of Bla for Rgx-121 to Treat Patients With Mps Ii

THOMSON REUTERS
·
Aug 19

REGENXBIO Is Maintained at Overweight by Barclays

Dow Jones
·
Aug 08

RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 08

Regenxbio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

BRIEF-Regenxbio Inc - Phase Iib/Iii Trial To Be Initiated For Diabetic Retinopathy

Reuters
·
Aug 07

Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate

Benzinga
·
Aug 07